|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sheikh A, Hussain SA, Ghori Q, Naeem N,
Fazil A, Giri S, Sathian B, Mainali P and Al Tamimi DM: The
spectrum of genetic mutations in breast cancer. Asian Pac J Cancer
Prev. 16:2177–2185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Harbeck N, Penault-Llorca F, Cortes J,
Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J and Cardoso F:
Breast cancer. Nat Rev Dis Primers. 5:662019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Early Breast Cancer Trialists'
Collaborative Group (EBCTCG), ; Davies C, Godwin J, Gray R, Clarke
M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, et al: Relevance
of breast cancer hormone receptors and other factors to the
efficacy of adjuvant tamoxifen: Patient-level meta-analysis of
randomised trials. Lancet. 378:771–784. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Piccart-Gebhart MJ, Procter M,
Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga
J, Bell R, Jackisch C, et al: Trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer. N Engl J Med.
353:1659–1672. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garrido-Castro AC, Lin NU and Polyak K:
Insights into molecular classifications of triple-negative breast
cancer: Improving patient selection for treatment. Cancer Discov.
9:176–198. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lefebvre V, Dumitriu B, Penzo-Méndez A,
Han Y and Pallavi B: Control of cell fate and differentiation by
Sry-related high-mobility-group box (Sox) transcription factors.
Int J Biochem Cell Biol. 39:2195–2214. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gnerlich JL, Ding X, Joyce C, Turner K,
Johnson CD, Chen H, Abood GJ, Pappas SG and Aranha GV: Increased
SOX9 expression in premalignant and malignant pancreatic neoplasms.
Ann Surg Oncol. 26:628–634. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang JQ, Wei FK, Xu XL, Ye SX, Song JW,
Ding PK, Zhu J, Li HF, Luo XP, Gong H, et al: SOX9 drives the
epithelial-mesenchymal transition in non-small-cell lung cancer
through the Wnt/β-catenin pathway. J Transl Med. 17:1432019.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang L, Zhang Z, Yu X, Li Q, Wang Q, Chang
A, Huang X, Han X, Song Y, Hu J, et al: SOX9/miR-203a axis drives
PI3K/AKT signaling to promote esophageal cancer progression. Cancer
Lett. 468:14–26. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Mesquita P, Freire AF, Lopes N, Gomes R,
Azevedo D, Barros R, Pereira B, Cavadas B, Pópulo H, Boaventura P,
et al: Expression and clinical relevance of SOX9 in gastric cancer.
Dis Markers. 2019:82670212019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yang H, Zhou Y, Mo J, Xiang Q, Qin M, Liu
W, Shang J, Yang Q, Xu W, Yang G, et al: SOX9 represses hepatitis B
virus replication through binding to HBV EnhII/Cp and inhibiting
the promoter activity. Antiviral Res. 177:1047612020. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xue Y, Lai L, Lian W, Tu X, Zhou J, Dong
P, Su D, Wang X, Cao X, Chen Y and Wang Q: SOX9/FXYD3/Src axis is
critical for ER+ breast cancer stem cell function. Mol
Cancer Res. 17:238–249. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trapnell C, Pachter L and Salzberg SL:
TopHat: Discovering splice junctions with RNA-Seq. Bioinformatics.
25:1105–1111. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Trapnell C, Roberts A, Goff L, Pertea G,
Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL and Pachter L:
Differential gene and transcript expression analysis of RNA-seq
experiments with TopHat and cufflinks. Nat Protoc. 7:562–578. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jana S, Madhu Krishna B, Singhal J, Horne
D, Awasthi S, Salgia R and Singhal SS: SOX9: The master regulator
of cell fate in breast cancer. Biochem Pharmacol. 174:1137892020.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Carneiro BA and El-Deiry WS: Targeting
apoptosis in cancer therapy. Nat Rev Clin Oncol. 17:395–417. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Al-Mahmood S, Sapiezynski J, Garbuzenko OB
and Minko T: Metastatic and triple-negative breast cancer:
Challenges and treatment options. Drug Deliv Transl Res.
8:1483–1507. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Siu MKY, Jiang YX, Wang JJ, Leung THY, Han
CY, Tsang BK, Cheung ANY, Ngan HYS and Chan KKL: Hexokinase 2
regulates ovarian cancer cell migration, invasion and stemness via
FAK/ERK1/2/MMP9/NANOG/SOX9 signaling cascades. Cancers (Basel).
11:8132019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W, Wu Y, Hou B, Wang Y, Deng D, Fu Z
and Xu Z: A SOX9-AS1/miR-5590-3p/SOX9 positive feedback loop drives
tumor growth and metastasis in hepatocellular carcinoma through the
Wnt/β-catenin pathway. Mol Oncol. 13:2194–2210. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grimm D, Bauer J, Wise P, Krüger M,
Simonsen U, Wehland M, Infanger M and Corydon TJ: The role of SOX
family members in solid tumours and metastasis. Semin Cancer Biol.
67:122–153. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JY, Bai Y, Jayne LA, Abdulkader F,
Gandhi M, Perreau T, Parikh SV, Gardner DS, Davidson AJ, Sander V,
et al: SOX9 promotes stress-responsive transcription of VGF nerve
growth factor inducible gene in renal tubular epithelial cells. J
Biol Chem. 295:16328–16341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Prieto-Conde MI, Jiménez C, García-Álvarez
M, Ramos F, Medina A, Cuello R, Balanzategui A, Alonso JM,
Sarasquete ME, Queizán JA, et al: Identification of
relapse-associated gene mutations by next-generation sequencing in
low-risk acute myeloid leukaemia patients. Br J Haematol.
189:718–730. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen Y and Hu J: Nucleophosmin1 (NPM1)
abnormality in hematologic malignancies, and therapeutic targeting
of mutant NPM1 in acute myeloid leukemia. Ther Adv Hematol.
11:20406207198998182020. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zeng D, Xiao Y, Zhu J, Peng C, Liang W and
Lin H: Knockdown of nucleophosmin 1 suppresses proliferation of
triple-negative breast cancer cells through activating
CDH1/Skp2/p27kip1 pathway. Cancer Manag Res. 11:143–156. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fu B, Meng W, Zeng X, Zhao H, Liu W and
Zhang T: TXNRD1 is an unfavorable prognostic factor for patients
with hepatocellular carcinoma. Biomed Res Int. 2017:46981672017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Poerschke RL and Moos PJ: Thioredoxin
reductase 1 knockdown enhances selenazolidine cytotoxicity in human
lung cancer cells via mitochondrial dysfunction. Biochem Pharmacol.
81:211–221. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jaiswal PK, Koul S, Palanisamy N and Koul
HK: Eukaryotic translation initiation factor 4 gamma 1 (EIF4G1): A
target for cancer therapeutic intervention? Cancer Cell Int.
19:2242019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han X, Piao L, Xu X, Luo F, Liu Z and He
X: NSD2 promotes renal cancer progression through stimulating
Akt/Erk signaling. Cancer Manag Res. 12:375–383. 2020. View Article : Google Scholar : PubMed/NCBI
|
